Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RDY vs TAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: RDY 0 – 5 TAK (1 Tie) Matrix Metrics: RDY 3 – 7 TAK

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Dr. Reddy's Laboratories Limited (RDY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.69 (31.6x Forward P/E, 9.1% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RDY vs TAK
RDY NYSE
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.69
-0.34% 1D
Market Cap $12.3B
TTM Revenue $3.53B
Forward P/E 31.6x
Beta / 30D Vol 0.39β · 24% Vol
Unified Composite Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 68
RSI-14: 67.9 · SMA20: $14.22 · SMA50: $13.10
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 72
RSI-14: 72.3 · SMA20: $20.71 · SMA50: $19.46

6-Pillar Scorecard Institutional Category Breakdown (RDY 0 – 5 TAK)

Columns: Metric · RDY · TAK
1. Valuation Multiples TAK
Forward P/E 31.6x 12.7x
Trailing P/E 41.0x N/M
PEG Ratio 2.02x 0.47x
EV / Revenue 3.5x 2.6x
2. Growth & Scale TAK
Revenue Growth (YoY) -1.5% +6.7%
Earnings Growth (YoY) -35.7% -9.8%
TTM Revenue (USD) $3.53B $25.7B
Market Cap $12.3B $67.5B
3. Profitability & Quality TAK
Gross Margin 49.5% 64.8%
Operating Margin 9.1% 16.6%
Net Profit Margin 8.5% 0.9%
Return on Equity (ROE) 7.3% 0.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $534M EBITDA $7.48B EBITDA
Cash Flow Margin 15.1% EBITDA Mgn 29.1% EBITDA Mgn
Net Cash / Leverage $0.82 Book/Sh · 7.3% ROE $14.68 Book/Sh · 0.6% ROE
Dividend Yield 0.57% 2.92%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 22.4% (5th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 40.4% of Rev ($1.43B) 48.2% of Rev ($12.4B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RDY (3) vs TAK (7)
Institutional Metric RDY TAK Criterion Row Edge
Market Capitalization
Scale
$12.3B $67.5B Larger Scale TAK
Trailing P/E Ratio
Valuation
41.0x N/M Lower Multiple RDY
Forward P/E Ratio
Valuation
31.6x 12.7x Lower Multiple TAK
Revenue Growth (YoY)
Growth
-1.5% +6.7% Higher Growth TAK
Operating Margin (TTM)
Profitability
9.1% 16.6% Higher Margin TAK
Net Profit Margin
Profitability
8.5% 0.9% Higher Margin RDY
Return on Equity (ROE)
Capital Efficiency
7.3% 0.6% Higher ROE RDY
52-Week Range Position
Momentum
77% ($11–$16) 97% ($14–$22) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
0.39β · 24% Vol -0.02β · 22% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
34.7 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$3.53B $25.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.5% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.02x PEG · 3.5x EV/Rev 0.47x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$534M EBITDA ($0.82 Book/Sh · 7.3% ROE) $7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RDY +2.5 pp
RDY: +12.39% · TAK: +9.89%
3M Horizon RDY +1.16 pp
RDY: +20.91% · TAK: +19.75%
6M Horizon TAK +22.44 pp
RDY: +8.01% · TAK: +30.45%
1Y Horizon TAK +45.88 pp
RDY: +5.91% · TAK: +51.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDY vs TAK. Trailing 12-month operating profitability (RDY 9.1% vs TAK 16.6%) and valuation multiples (RDY 31.6x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

RDY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.53B
Gross Margin49.5%
Op. Margin9.1%
ROE / Fwd P/E7.3% · 31.6x
TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RDY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RDY Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.3B market capitalization and 9.1% operating margin.
OpEx & R&D Reinvestment 40.4% of Rev ($1.43B)
90D Engineering Disclosures 0 Published
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published

Investor FAQ RDY vs TAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Dr. Reddy's Laboratories Limited (RDY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.69 (31.6x Forward P/E, 9.1% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technically, RDY sits in a Markup phase (RSI 67.9, UNCLASSIFIED options structure) and TAK sits in a Markup phase (RSI 72.3, UNCLASSIFIED options structure).

TAK leads the Growth & Scale pillar: RDY posts -1.5% YoY revenue growth and -35.7% YoY earnings growth on $3.53B TTM revenue (49.5% gross margin, 9.1% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, RDY generates $3.53B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, RDY deploys 40.4% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.

TAK screens cheaper on headline valuation multiples. RDY trades at 31.6x Forward P/E, 41.0x Trailing P/E, 2.02x PEG, and 3.5x EV/Revenue (15.1% EBITDA margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RDY (7.3% ROE) versus TAK (0.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RDY carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 24% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Research Suite

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.